143 related articles for article (PubMed ID: 1467385)
21. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
Viguera AC; Baldessarini RJ; Hegarty JD; van Kammen DP; Tohen M
Arch Gen Psychiatry; 1997 Jan; 54(1):49-55. PubMed ID: 9006400
[TBL] [Abstract][Full Text] [Related]
22. Schizophrenic relapse after drug withdrawal is predictable.
Dencker SJ; Malm U; Lepp M
Acta Psychiatr Scand; 1986 Feb; 73(2):181-5. PubMed ID: 3705994
[TBL] [Abstract][Full Text] [Related]
23. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
[TBL] [Abstract][Full Text] [Related]
24. Methylphenidate challenge as a predictor of relapse in schizophrenia.
Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
[TBL] [Abstract][Full Text] [Related]
25. Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems.
Keks NA; Copolov DL; Kulkarni J; Mackie B; Singh BS; McGorry P; Rubin RT; Hassett A; McLaughlin M; van Riel R
Biol Psychiatry; 1990 Jun; 27(11):1203-15. PubMed ID: 2354227
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration.
Möller HJ; Kissling W; Lang C; Doerr P; Pirke KM; von Zerssen D
Am J Psychiatry; 1982 Dec; 139(12):1571-5. PubMed ID: 7149056
[TBL] [Abstract][Full Text] [Related]
27. Association of high prolactin levels and neuroleptics immediately postpartum.
LaFleur P; Van Norman J; Nader S; Shapiro L; Peabody CA
J Neuropsychiatry Clin Neurosci; 1990; 2(1):115. PubMed ID: 2136057
[No Abstract] [Full Text] [Related]
28. Prolactin shifts after neuroleptic withdrawal.
Green AI; Faraone SV; Brown WA
Psychiatry Res; 1990 Jun; 32(3):213-9. PubMed ID: 1975101
[TBL] [Abstract][Full Text] [Related]
29. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Wistedt B; Palmstierna T
J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
[TBL] [Abstract][Full Text] [Related]
30. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients.
van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Condray R; Peters JL
Neuropsychopharmacology; 1996 Apr; 14(4):275-83. PubMed ID: 8924195
[TBL] [Abstract][Full Text] [Related]
31. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
Elizur A; Segal Z; Yeret A; Ben-David M
Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
[No Abstract] [Full Text] [Related]
32. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
Kuhs H; Folkerts H
Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
[TBL] [Abstract][Full Text] [Related]
33. Serum prolactin and clinical state during neuroleptic treatment and withdrawal.
Laughren TP; Brown WA; Williams BW
Am J Psychiatry; 1979 Jan; 136(1):108-10. PubMed ID: 758812
[No Abstract] [Full Text] [Related]
34. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
[TBL] [Abstract][Full Text] [Related]
36. Dosing the antipsychotic medication olanzapine.
Nemeroff CB
J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
[TBL] [Abstract][Full Text] [Related]
37. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
[TBL] [Abstract][Full Text] [Related]
38. Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients.
Neylan TC; van Kammen DP; Kelley ME; Peters JL
Arch Gen Psychiatry; 1992 Aug; 49(8):643-9. PubMed ID: 1637254
[TBL] [Abstract][Full Text] [Related]
39. L-dopa challenge and relapse in schizophrenia.
Davidson M; Keefe RS; Mohs RC; Siever LJ; Losonczy MF; Horvath TB; Davis KL
Am J Psychiatry; 1987 Jul; 144(7):934-8. PubMed ID: 2886063
[TBL] [Abstract][Full Text] [Related]
40. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free.
Nofzinger EA; van Kammen DP; Gilbertson MW; Gurklis JA; Peters JL
Biol Psychiatry; 1993 Jun 1-15; 33(11-12):829-35. PubMed ID: 8104041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
